
Privacy notice | Accessibility statement | Terms and conditions | Login | Contact |
UK data driving real-world evidence
Bibliography
Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 6 April 2021) and papers are listed below and in the PDF below.
If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.
Download:
(PDF, 5MB, 226 pages)This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website.
“Defining Clinically-Relevant Target Populations Using Real-World Data to Guide the Design of Representative Antidiabetic Drug Trials”, Clin Pharmacol Ther, 2021.
, “Infectious Disease Burden and the Risk of Alzheimer's Disease: A Population-Based Study”, J Alzheimers Dis, 2021.
, “Prescribing Trends of Antidepressants and Psychotropic Coprescription for Youths in UK Primary Care, 2000-2018”, J Affect Disord, vol. 287, pp. 19-25, 2021.
, “SGLT-2 inhibitors and the risk of hospitalization for community-acquired pneumonia: A population-based cohort study”, Pharmacoepidemiol Drug Saf, 2021.
, “Adaptive Treatment Strategies with Survival Outcomes: An Application to the Treatment of Type 2 Diabetes using a Large Observational Database”, Am J Epidemiol, 2020.
, “Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study”, Circulation, vol. 141, pp. 549-559, 2020.
, “The Association between Oral Anticoagulants and Cancer Incidence among Individuals with Nonvalvular Atrial Fibrillation”, Thromb Haemost, 2020.
, “Cardiotoxicity of Sequential Aromatase Inhibitors Use in Women with Breast Cancer”, Am J Epidemiol, 2020.
, “Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes”, Diabet Med, 2020.
, “Trends in acid suppressant drug prescriptions in primary care in the UK: a population-based cross-sectional study”, BMJ Open, vol. 10, p. e041529, 2020.
, , , , “Androgen Deprivation Therapy for Prostate Cancer and the Risk of Rheumatoid Arthritis: A Population-Based Cohort Study”, Drug Saf, 2019.
, “Cardiovascular and cerebrovascular safety of testosterone replacement therapy among aging men with low testosterone levels: a cohort study.”, Am J Med, 2019.
, “Dipeptidyl Peptidase-4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes”, Diabetes Care, 2019.
, “Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes”, Diabetes Care, vol. 42, pp. e150-e152, 2019.
, “Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study”, Br J Clin Pharmacol, 2019.
, , , “Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study”, Bmj, vol. 363, p. k4209, 2018.
, “Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer”, Ann Oncol, vol. 29, pp. 744-748, 2018.
, “Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study”, Bmj, vol. 360, p. k872, 2018.
, “Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy”, Diabetes Care, vol. 41, pp. 2330-2338, 2018.
, “Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study”, Bmj, vol. 363, p. k4880, 2018.
, “Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes”, Epidemiology, vol. 29, pp. 246-253, 2018.
, “Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia”, Am J Med, vol. 131, pp. 317.e11-317.e22, 2018.
, “Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study”, Bmj, vol. 362, p. k2693, 2018.
, “Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes”, Epidemiology, vol. 29, pp. 904-912, 2018.
, “Androgen Deprivation Therapy and the Risk of Anemia in Men with Prostate Cancer”, Epidemiology, vol. 28, pp. 712-718, 2017.
, “Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer”, J Clin Oncol, vol. 35, pp. 201-207, 2017.
, “Androgen deprivation therapy for prostate cancer and the risk of hospitalisation for community-acquired pneumonia”, Thorax, vol. 72, pp. 596-597, 2017.
, “Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes”, J Clin Oncol, vol. 35, pp. 3647-3653, 2017.
, “Metformin and the incidence of viral associated cancers in patients with type 2 diabetes”, Int J Cancer, vol. 141, pp. 121-128, 2017.
, “Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events”, Diabetes Care, vol. 40, pp. 1506-1513, 2017.
, “Prolactin-Elevating Antipsychotics and the Risk of Endometrial Cancer”, J Clin Psychiatry, vol. 78, pp. 714-719, 2017.
, “The use of drugs acting on the renin-angiotensin system and the incidence of pancreatic cancer”, Br J Cancer, vol. 116, pp. 103-108, 2017.
, “Androgen Deprivation Therapy and the Incidence of Inflammatory Bowel Disease in Patients With Prostate Cancer”, Am J Epidemiol, vol. 184, pp. 15-22, 2016.
, “Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism”, Eur Urol, vol. 70, pp. 56-61, 2016.
, “Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus”, JAMA Intern Med, vol. 176, pp. 1474-1481, 2016.
, “Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink”, Bmj, vol. 355, p. i5340, 2016.
, “A Multicenter Observational Study of Incretin-based Drugs and Heart Failure”, N Engl J Med, vol. 374, pp. 1145-54, 2016.
, “Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer”, Eur Urol, vol. 70, pp. 808-815, 2016.
, “Pioglitazone use and risk of bladder cancer: population based cohort study”, Bmj, vol. 352, p. i1541, 2016.
, “Use of Calcium Channel Blockers and Risk of Breast Cancer: A Population-based Cohort Study”, Epidemiology, vol. 27, pp. 594-601, 2016.
, “The Use of Telmisartan and the Incidence of Cancer”, Am J Hypertens, vol. 29, pp. 1358-1365, 2016.
, “5alpha-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer”, JAMA Oncol, vol. 1, pp. 314-20, 2015.
, “The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death”, Can J Diabetes, vol. 39, pp. 383-9, 2015.
, “Dipeptidyl peptidase-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 diabetes”, Diabetes Obes Metab, vol. 17, pp. 379-85, 2015.
, “Incretin-based drugs and the risk of congestive heart failure”, Diabetes Care, vol. 38, pp. 277-84, 2015.
,